We selected the 501Mel cell line since (i) these cells display a melanocytic differentiation state as the majority of diagnosticated melanoma, (ii) they harbor the BRAF(V600E) mutation as ~50% of cutaneous melanoma, (iii) they are highly sensitive to BRAFi with an IC50 value of 0.45 μM to vemurafenib [PLX4032] (Halaban et al,2010; Corre et al,2018), and importantly (iv) they are unable to generate tumor in nude mice (Ohanna et al,2011). This evidence concerns the gene BRAF and cutaneous melanoma.